Soligenix, Inc. (SNGX) News
Filter SNGX News Items
SNGX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
SNGX News Highlights
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
-
404 Page not found Error: Page not found
The requested URL was not found on this server.
Latest SNGX News From Around the Web
Below are the latest news stories about SOLIGENIX INC that investors may wish to consider to help them evaluate SNGX as an investment opportunity.
Soligenix begins enrolling subjects in cutaneous T-cell lymphoma treatment trialThe randomised, placebo-controlled FLASH2 trial aims to enrol nearly 80 patients with early-stage cutaneous T-cell lymphoma. |
Soligenix initiates confirmatory Phase 3 trial of HyBryteSoligenix (SNGX) announced that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte in the treatment of cutaneous T-cell lymphoma, CTCL. The confirmatory Phase 3 study builds on the previous statistically significant Phase 3 study, as well as a recent successful comparative study and an ongoing investigator-initiated study, each further supporting the design of the FLASH2 clinical trial. Published first on TheFly – the ultimate source for real-time, market-movi |
SNGX: Phase 3 FLASH2 Trial of HyBryte in CTCL Underway…By David Bautz, PhD NASDAQ:SNGX READ THE FULL SNGX RESEARCH REPORT Business Update Phase 3 FLASH2 Trial of HyBryte in CTCL is Underway On December 16, 2024, Soligenix, Inc. (NASDAQ:SNGX) announced that patient enrollment has opened up for the confirmatory Phase 3 FLASH2 (Fluorescent Light Activated Synthetic Hypericin 2) trial of HyBryte™ in patients with cutaneous T cell lymphoma (CTCL). The |
Soligenix Initiates Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell LymphomaSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte™ (synthetic hypericin) in the treatment of cutaneous T-cell lymphoma (CTCL). The confirmatory Phase 3 study (Fluorescent Light Activated Synthetic Hypericin 2, FLASH2), builds on the |
EXCLUSIVE: Soligenix Starts Confirmatory Late-Stage Trial For HyBryte For Type Of Blood CancerOn Monday, Soligenix, Inc. (NASDAQ:SNGX) said it has opened patient enrollment for its confirmatory Phase 3 study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL). The confirmatory Phase 3 study, FLASH2, builds on the previous statistically significant Phase 3 (FLASH) study, as well as a recent comparative study (HPN-CTCL-04) and an ongoing investigator-initiated study, each further supporting the design of the FLASH2 clinical trial. Also Read: Soligenix Kickstarts D |
Winter 2024 Investor Summit Virtual: Q4 Presentations Now Available for On-Demand ViewingInvestor Summit Group, committed to advancing the MicroCap and SmallCap investment community, announces that the November 21, 2024 Winter Investor Summit Virtual Conference presentations are now available for on-demand viewing. Participants and those ... |
HyBryte™ Clinical Results Demonstrate Continued Improvement Post-TreatmentSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that analysis of the post-treatment data from the open-label study (protocol HPN-CTCL-04) comparing HyBryte™ (synthetic hypericin) to Valchlor® (mechlorethamine) has demonstrated continued improvement in HyBryte™ treated patients and their individual lesions even after stop |
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025ATLANTIC CITY, NJ / ACCESSWIRE / November 27, 2024 /DealFlow Events is pleased to announce the initial lineup of companies participating in The Microcap Conference, set for January 28-30 in Atlantic City, NJ. Now in its second year, the event is a ... |
Soligenix Announces Formation of European Medical Advisory Board for Cutaneous T-Cell LymphomaSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today the formation of a European Medical Advisory Board (MAB) to provide additional medical/clinical strategic guidance to the Company as it advances its confirmatory Phase 3 multicenter, double-blind, placebo-controlled study evaluating the safety and efficacy of HyBryte™ (synt |
Soligenix to Present at November 21st Virtual Investor Summit Microcap EventPRINCETON, NJ / ACCESSWIRE / November 15, 2024 / Soligenix, Inc. (Nasdaq:SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical ... |